Innovations + Investments in Healthcare Summit 2015

Breaking World Pharma News

Midday naps associated with reduced blood pressure and fewer medications

Midday naps are associated with reduced blood pressure levels and prescription of fewer antihypertensive medications, according to research presented at ESC Congress by Dr Manolis Kallistratos, a cardiologist at Asklepieion Voula General Hospital in Athens, Greece. The purpose of this prospective study was to assess the effect of midday sleep on blood pressure (BP) levels in hypertensive patients.

Read more...

A healthy environment can prevent heart disease

Cardiovascular diseases (CVD), including heart disease and stroke, are the number 1 killer worldwide and in Europe, where they cause the death of over 10 000 people daily, i.e. more than all cancers combined (1). Recent scientific evidence shows that air and noise pollution are environmental health risks which have severe consequences on heart health (2-5).

Read more...

Novo Nordisk plans 2 billion US dollar investment in new production facilities in Clayton, North Carolina and Måløv, Denmark

Novo NordiskNovo Nordisk plans to invest an estimated 2 billion US dollars over the next five years in new production facilities in Clayton, North Carolina, US and Måløv, Denmark. The expansions will help Novo Nordisk meet the increasing worldwide demand for its diabetes medicines.

Read more...

Adverse effects of common prostate enlargement and hair growth drugs

Twenty-five percent of men currently taking Finasteride or Dutasteride, popularly known as Proscar and Avodart, for the treatment of benign prostate enlargement (BPH), appear not to benefit from taking these medications. Those prescribed Propecia or Avodart for male pattern hair loss (known as alopecia) are also at risk for adverse events elicited by these drugs.

Read more...

Scientists discover electrical control of cancer cell growth

The molecular switches regulating human cell growth do a great job of replacing cells that die during the course of a lifetime. But when they misfire, life-threatening cancers can occur. Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.

Read more...

AstraZeneca and Peregrine Pharmaceuticals to collaborate on immuno-oncology combination clinical trial

AstraZenecaAstraZeneca today announced that it has entered into a clinical trial collaboration with Peregrine Pharmaceuticals, Inc. to evaluate the safety and efficacy of Peregrine's investigational phosphatidylserine (PS)-signalling pathway inhibitor, bavituximab, in combination with AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736).

Read more...

Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications

NovartisNovartis announced today that it has entered into an agreement to acquire all remaining rights to Ofatumumab from GlaxoSmithKline plc (GSK). Ofatumumab, a fully human monoclonal antibody which targets CD20, is being developed for relapsing remitting multiple sclerosis (RRMS) and other autoimmune indications.

Read more...

World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]